Status:
COMPLETED
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
Lead Sponsor:
AstraZeneca
Conditions:
Non Small Cell Lung Carcinoma
Eligibility:
All Genders
19-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and...
Eligibility Criteria
Inclusion
- Pathological Diagnosis of local advanced/metastatic Non Small Cell Lung Carcinoma
- Previously failed the first-line chemotherapy
- Patient who can provide sample for EGFR mutation test
Exclusion
- Central Nervous System metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation
- Any evidence of clinically active interstitial lung disease
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT00608868
Start Date
January 1 2007
End Date
January 1 2009
Last Update
September 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Daegu, South Korea